a Sanofi company, has launched the fifth annual Patient Advocacy
Leadership (PAL) Awards program for non-profit organizations that serve
the lysosomal storage disorder (LSD) patient community. The PAL Awards
program seeks to spark innovative collaborations in...
a Sanofi company, today announced that it has entered into a definitive
agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a rare
disease therapy, indicated for the treatment of symptomatic or
progressive medullary thyroid carcinoma in patients with...
a Sanofi company, announced today that the first pediatric patient has
begun treatment in a Phase 1/2 clinical trial focused on evaluating the
investigational therapy olipudase alfa. Olipudase alfa is an enzyme
replacement therapy being studied for the treatment...
a Sanofi company, announced today that the U.S. Food and Drug
Administration (FDA) has granted Breakthrough Therapy designation to
olipudase alfa. This enzyme replacement therapy is being investigated
for the treatment of patients with nonneurological...